Congress caps what patients pay for drugs—$2,000 a year, starting 2026
S. 529 — Capping Prescription Costs Act of 2025 · Filed by Raphael Warnock (D-GA) · 13 cosponsors · Introduced Feb 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps annual out-of-pocket costs for prescription drugs covered by health insurance plans at $2,000 per individual and $4,000 per family starting in 2026, with the cap adjusted annually for inflation. The cap applies to qualified health plans under the Affordable Care Act, group health plans, and self-insured employer plans.
Why we flagged it
The bill's operative mechanism is a direct, enforceable ceiling on patient out-of-pocket drug costs across all major insurance channels (ACA, group, self-insured). It is a consumer protection measure, not a market intervention or subsidy.
What the text implies
- The $2,000/$4,000 cap may shift cost burden upstream to insurers and pharmacy benefit managers, potentially increasing premiums or reducing drug formulary breadth if not offset by manufacturer pricing pressure or negotiation.
- The cap does not address drugs not covered by a plan; patients using non-formulary drugs remain exposed to full retail prices, creating a two-tier system.
The full analysis lists 4 implications of this text.
Who stands to gain
patients with chronic conditions requiring expensive medications; low-income and middle-income families with high drug costs